400-998-5282
专注多肽 服务科研
400-998-5282
专注多肽 服务科研
作为KTWGQYWQV，ITDQVPFSV是一种gp100表位，在HLA-A2的背景下被体内肿瘤浸润淋巴细胞（TIL）识别。PMEL 17可能是一种黑色素生成酶。
编号：143927
CAS号：162558-10-3
单字母：H2N-ITDQVPFSV-OH
作为KTWGQYWQV，ITDQVPFSV是一种gp100表位，在HLA-A2的背景下被体内肿瘤浸润淋巴细胞（TIL）识别。PMEL 17可能是一种黑色素生成酶。
As KTWGQYWQV, ITDQVPFSV is a gp100 epitope that is recognized in the context of HLA-A2 by tumor-infiltrating lymphocytes (TIL) in vivo. PMEL 17 could be a melanogenic enzyme.
一种黑色素生成酶，在HLA-A2的背景下被体内肿瘤冲洗淋巴细胞（TIL）识别。
A melanogenic enzyme that is recognized in the context of HLA-A2 by tumo-rinfiltrating lymphocytes (TIL) in vivo.
Peptide H-ITDQVPFSV-OH is a Research Peptide with significant interest within the field academic and medical research. Recent citations using H-ITDQVPFSV-OH include the following: Functional characterization of CTL against gp100 altered peptide ligands SO Dionne, MH Smith, FM Marincola - Cancer Immunology , 2003 - Springerhttps://link.springer.com/article/10.1007/s00262-002-0358-3 Antigen presentation of a modified tumor-derived peptide by tumor infiltrating lymphocytes SO Dionne, MH Smith, FM Marincola, DF Lake - Cellular immunology, 2001 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0008874901918933 Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100209-2M peptide SL Meijer, A Dols, SM Jensen, HM Hu - Journal of , 2007 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2007/07000/Adoptive_Cellular_Therapy_With_Tumor_Vaccine.00008.aspx Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine OY Borbulevych , TK Baxter, Z Yu - The Journal of , 2005 - journals.aai.orghttps://journals.aai.org/jimmunol/article/174/8/4812/1745 An HLA-A2 polyepitope vaccine for melanoma immunotherapy L Mateo, J Gardner, Q Chen, C Schmidt - The Journal of , 1999 - journals.aai.orghttps://journals.aai.org/jimmunol/article/163/7/4058/105313 Recombinant Virus Vaccination against"Self"Â\x9d Antigens UsingAnchor-fixed Immunogens KR Irvine, MR Parkhurst, EP Shulman, JP Tupesis - Cancer research, 1999 - AACRhttps://aacrjournals.org/cancerres/article-abstract/59/11/2536/505166 Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation J Chapiro, S Claverol, F Piette, W Ma - The Journal of , 2006 - journals.aai.orghttps://journals.aai.org/jimmunol/article/176/2/1053/73604 Peptide-specific CD8+ T-cell evolution in vivo: Response to peptide vaccination with Melan-A/MART-1 E Jager, H Höhn, A Necker, R Förster - journal of cancer, 2002 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.10165 Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination DJ Powell Jr, SA Rosenberg - Journal of immunotherapy, 2004 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2004/01000/Long_Term_Survival_of_Anti_Tumor_Lymphocytes.4.aspx Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund\s adjuvant for multipeptide melanoma vaccines CL Slingluff , GR Petroni , ME Smolkin - Journal of , 2010 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2010/07000/immunogenicity_for_cd8__and_cd4__t_cells_of_2.8.aspx Generation of melanoma-specific cytotoxic T lymphocytes for allogeneic immunotherapy A Nolte, C Scheffold, J Slotty, C Huenefeld - Journal of , 2003 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2003/05000/Response_Rates_of_Patients_With_Metastatic.9.aspx
| DOI | 名称 | |
|---|---|---|
| 10.1615/critrevimmunol.v18.i1-2.30 | Identification of peptides for immunotherapy of cancer. It is worth the effort | 下载 |
多肽H2N-Ile-Thr-Asp-Gln-Val-Pro-Phe-Ser-Val-COOH的合成步骤：
1、合成CTC树脂：称取1.76g CTC Resin（如初始取代度约为1.04mmol/g）和2.2mmol Fmoc-Val-OH于反应器中，加入适量DCM溶解氨基酸（需要注意，此时CTC树脂体积会增大好几倍，避免DCM溶液过少），再加入5.49mmol DIPEA（Mw：129.1,d：0.740g/ml），反应2-3小时后，可不抽滤溶液，直接加入1ml的HPLC级甲醇，封端半小时。依次用DMF洗涤2次，甲醇洗涤1次，DCM洗涤一次，甲醇洗涤一次，DCM洗涤一次，DMF洗涤2次（这里使用甲醇和DCM交替洗涤，是为了更好地去除其他溶质，有利于后续反应）。得到 Fmoc-Val-CTC Resin。结构图如下：
2、脱Fmoc：加3倍树脂体积的20%Pip/DMF溶液，鼓氮气30分钟，然后2倍树脂体积的DMF 洗涤5次。得到 H2N-Val-CTC Resin 。（此步骤脱除Fmoc基团，茚三酮检测为蓝色，Pip为哌啶）。结构图如下：
3、缩合：取5.49mmol Fmoc-Ser(tBu)-OH 氨基酸，加入到上述树脂里，加适当DMF溶解氨基酸，再依次加入10.98mmol DIPEA，5.22mmol HBTU。反应30分钟后，取小样洗涤，茚三酮检测为无色。用2倍树脂体积的DMF 洗涤3次树脂。（洗涤树脂，去掉残留溶剂，为下一步反应做准备）。得到Fmoc-Ser(tBu)-Val-CTC Resin。氨基酸：DIPEA：HBTU：树脂=3：6：2.85：1（摩尔比）。结构图如下：
4、依次循环步骤二、步骤三，依次得到
H2N-Ser(tBu)-Val-CTC Resin
Fmoc-Phe-Ser(tBu)-Val-CTC Resin
H2N-Phe-Ser(tBu)-Val-CTC Resin
Fmoc-Pro-Phe-Ser(tBu)-Val-CTC Resin
H2N-Pro-Phe-Ser(tBu)-Val-CTC Resin
Fmoc-Val-Pro-Phe-Ser(tBu)-Val-CTC Resin
H2N-Val-Pro-Phe-Ser(tBu)-Val-CTC Resin
Fmoc-Gln(Trt)-Val-Pro-Phe-Ser(tBu)-Val-CTC Resin
H2N-Gln(Trt)-Val-Pro-Phe-Ser(tBu)-Val-CTC Resin
Fmoc-Asp(OtBu)-Gln(Trt)-Val-Pro-Phe-Ser(tBu)-Val-CTC Resin
H2N-Asp(OtBu)-Gln(Trt)-Val-Pro-Phe-Ser(tBu)-Val-CTC Resin
Fmoc-Thr(tBu)-Asp(OtBu)-Gln(Trt)-Val-Pro-Phe-Ser(tBu)-Val-CTC Resin
H2N-Thr(tBu)-Asp(OtBu)-Gln(Trt)-Val-Pro-Phe-Ser(tBu)-Val-CTC Resin
Fmoc-Ile-Thr(tBu)-Asp(OtBu)-Gln(Trt)-Val-Pro-Phe-Ser(tBu)-Val-CTC Resin
以上中间结构，均可在专肽生物多肽计算器-多肽结构计算器中，一键画出。
最后再经过步骤二得到 H2N-Ile-Thr(tBu)-Asp(OtBu)-Gln(Trt)-Val-Pro-Phe-Ser(tBu)-Val-CTC Resin，结构如下：
5、切割：6倍树脂体积的切割液（或每1g树脂加8ml左右的切割液），摇床摇晃 2小时，过滤掉树脂，用冰无水乙醚沉淀滤液，并用冰无水乙醚洗涤沉淀物3次，最后将沉淀物放真空干燥釜中，常温干燥24小试，得到粗品H2N-Ile-Thr-Asp-Gln-Val-Pro-Phe-Ser-Val-COOH。结构图见产品结构图。
切割液选择：1）TFA：H2O=95%：5%、TFA：H2O=97.5%：2.5%
2）TFA：H2O：TIS=95%：2.5%：2.5%
3）三氟乙酸：茴香硫醚：1，2-乙二硫醇：苯酚：水=87.5%：5%：2.5%：2.5%：2.5%
（前两种适合没有容易氧化的氨基酸，例如Trp、Cys、Met。第三种适合几乎所有的序列。）
6、纯化冻干：使用液相色谱纯化，收集目标峰液体，进行冻干，获得蓬松的粉末状固体多肽。不过这时要取小样复测下纯度 是否目标纯度。
7、最后总结：
杭州专肽生物技术有限公司（ALLPEPTIDE https://www.allpeptide.com）主营定制多肽合成业务，提供各类长肽，短肽，环肽，提供各类修饰肽，如：荧光标记修饰（CY3、CY5、CY5.5、CY7、FAM、FITC、Rhodamine B、TAMRA等），功能基团修饰肽（叠氮、炔基、DBCO、DOTA、NOTA等），同位素标记肽（N15、C13），订书肽（Stapled Peptide）,脂肪酸修饰肽（Pal、Myr、Ste），磷酸化修饰肽（P-Ser、P-Thr、P-Tyr），环肽（酰胺键环肽、一对或者多对二硫键环），生物素标记肽，PEG修饰肽，甲基化修饰肽
以上所有内容，为专肽生物原创内容，请勿发布到其他网站上。
